Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with an unmet need for improved therapies. Responses to standard cytotoxic therapy in AML are often transient because of the emergence of chemotherapy-resistant disease. The MUC1-C oncoprotein governs critical pathways of tumorigenesis, including self-renewal and survival, and is aberrantly expressed in AML blasts and leukaemia stem cells (LSCs). However, a role for MUC1-C in linking leukaemogenesis and resistance to treatment has not been described. In this study, we demonstrate that MUC1-C overexpression is associated with increased leukaemia initiating --
| INTRODUCTION
Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by the emergence of a clonal population of primitive myeloid cells that exhibit a pattern of dysregulated growth and self-renewal. 1 Responses to cytotoxic agents, such as Cytarabine (Ara-C) and daunorubicin, are often observed in patients with AML; however, disease relapse is common because of the emergence of chemotherapy-resistant disease. 2 In this context, progression of AML is associated with genetic and epigenetic changes that promote aggressiveness and resistant disease.
There is a significant need to identify critical pathways that govern leukaemic progression and offer potential targets for novel therapeutics.
Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly expressed in cancer cells, including AML blasts. The oncogenic MUC1-C subunit drives critical hallmarks of malignant cells, including cell proliferation, resistance to apoptosis, self-renewal, and tissue invasion. [3] [4] [5] [6] Intriguingly, we have demonstrated that MUC1 is uniquely expressed by AML stem cells as compared to normal haematopoietic stem cells. 7 Primary AML cells expressing high levels of MUC1 efficiently induce leukaemic engraftment in a xenogeneic murine model, whereas MUC1 low expressing cells isolated from bone marrow of patients with active AML engraft normal haematopoietic elements.
The oncogenic function of the transmembrane MUC1-C subunit is dependent on the formation of homodimers, which are required for translocation to the nucleus and interactions with downstream effectors. [8] [9] [10] [11] The MUC1-C cytoplasmic domain is phosphorylated by c-Src and receptor tyrosine kinases, and interacts with effectors, such as b-catenin and NF-jB, that have been linked to transformation. In AML, MUC1-C associates with the b-catenin/TCF4 complex, which regulates cell proliferation and differentiation. 5, 12 Accumulation of b-catenin in the cytoplasm promotes its translocation to the nucleus as a cofactor for transcription factors of the T-cell factor (TCF) family and activates the transcription of Wnt/b-catenin target genes. MUC1-C facilitates the nuclear translocation of dephosphorylated active b-catenin that is necessary for inducing the expression of cyclin D1, MYC and survivin, a negative regulator of apoptosis. [13] [14] [15] Survivin also plays a role in the proliferation and survival of leukaemia induced by the internal tandem duplication of FLT3. 16 Moreover, survivin is highly expressed in AML progenitor cells and is predictive of poor clinical outcomes in patients with AML. 17 In this study, we demonstrate that MUC1-C signalling is critical for leukaemia progression and sensitivity to the cytotoxic agent Ara-C by a survivin-mediated mechanism. These findings emphasize the importance of MUC1-C as a target in AML and support targeting of MUC1-C with GO-203 in combination with Ara-C for the treatment of patients with AML.
| MATERIALS AND METHODS

| AML patient derived cells and cell lines
AML cell lines THP1, MV4-11 and MOLM-14 were purchased from ATCC and cultured in RPMI 1640 media (Cellgro, Manassas, VA) supplemented with heat-inactivated 10% Fetal Bovine Serum (Sigma, St. Louis, MO) and 100 IU/mL penicillin, and 100 lg/mL streptomycin (Cellgro, Manassas, VA). MOLM-14 and THP1 cells were transduced with a lentiviral vector expressing a MUC1
shRNA (MUC1shRNA; Sigma) or with a scrambled control shRNA vector (CshRNA; Sigma). 18 Alternatively, MUC1 knockdown was achieved using CRISPR/Cas9 technology as described. 19 For over- Bone marrow aspirates samples were obtained from patients with newly diagnosed AML as per an institutionally approved protocol. Mononuclear cells were isolated by ficoll density centrifugation.
For assessment of active b-catenin, CD34+ cells were isolated using the MiniMacs CD34 cell isolation kit (Miltenyi Biotec). The bulk AML cell population was used for in vivo experiments. Cells were treated with the MUC1-C inhibitor, GO-203, and as a control, the CP-2 peptide. 
Key Points
• MUC1-C is essential for AML establishment in an NSG mouse model.
• Targeting MUC1-C increases sensitivity of AML cells to cytarabine by down-regulating survivin.
reverse primers are Survivin Fwd (5 0 -TAATACCAGCACTTTGG
| Leukaemia engraftment in NSG mice
Bone marrow derived AML cells and AML cell lines were inoculated retro-orbitally into sublethally irradiated (300 rads) NOD-SCID IL2Rgammanull (NSG; 6 week old female) mice (Jackson Laboratories). After sacrifice, bone marrow and spleen cells were harvested and red blood cells (RBC) were removed using RBC lysis buffer (Sigma). Human AML engraftment was detected by staining cells with PE-conjugated anti-hCD45 and, as a control, FITC-conjugated antimouse mCD45. In certain experiments, the cells were also analysed for hCD34, hCD11C, hCD19 or hCD20
by multichannel flow cytometry using CellQuest, Diva or Kaluza software. In order to confirm AML blast morphology, cytospins were made from BM cells. The cells were then fixed in methanol and stained using the standard Wright Giemsa protocol. The cells were visualized with contrast light microscopy (Olympus AX70 microscope) using an oil immersion objective lens (9100).
| Immunoblot analysis
Cell lysates were prepared as described. 20 In addition, dead cells were detected by addition of 0.1 mg/mL propidium iodide (PI) and apoptotic cells were detected by Annexin V (FITC) apoptosis detection kit (BD Biosciences) using flow cytometry.
| Microarray gene expression data
Gene expression and clinical data were analysed for previously expression. Overall survival of both low and high expression groups were examined using "survival" package using R version 3.3.1.
| Statistical analysis
Data of two tested groups were compared using the Student's t-test.
P-Values less than. 05 were considered significant.
| RESULTS
| MUC1-C overexpression leads to increased leukaemogenicity in NSG mice
To investigate the role of MUC1-C in leukaemia induction in vivo, 
| MUC1 silencing leads to reduced nuclear translocation of b-catenin and decreased survivin expression
To evaluate the mechanism by which MUC1-C-mediated signalling promotes leukaemogenicity, we assessed the effect of silencing 
| Survivin overexpression in MUC1 silenced
AML cells leads to enhanced leukaemia induction
We next sought to investigate whether the effects of MUC1 silencing on leukaemogenicity is mediated by the down-regulation of survivin. In these studies, we first investigated MOLM-14 cells with a knockout of the MUC1 gene using a CRISPR/Cas9 approach (Figure 5A) . Consistent with the above findings, down-regulation of MUC1-C in the MOLM-14/CRISPR cells was associated with suppression of survivin expression ( Figure 5A ). We next overexpressed survivin in the CRISPR cells using lentiviral transduction ( Figure 5B , Figure S2D) . NSG mice were then inoculated with 10 9 10 3 MOLM14/CRISPR cells that were transduced with either survivin (CRISPR/survivin) or a control vector (CRISPR/vector). The mice were killed 21 days following inoculation, and the AML burden in F I G U R E 3 MUC1 silencing leads to reduced b-catenin levels and its decreased translocation to the nucleus. A, MUC1-C was silenced in MOLM-14 AML cells using lentiviral shRNA hairpin against MUC1-C. As a control, MOLM -14 cells were infected with control shRNA. For immunofluorescence evaluation of co-locolization of MUC1 and b-catenin to the nucleus, cytospins of MUC1-C silenced and control MOLM-14 cells were prepared and stained with antibodies against b-catenin (red) and MUC1-C (green). DAPI was used to visualize nuclei (blue). Images were acquired with a confocal Microscope (n = 3). B, Schematic representation of the MUC1-C subunit. MUC1-C consists of a 58 aa non-shed extracellular domain (ED), a 28 aa transmembrane domain (TM) and a 72 aa cytoplasmic domain (CD). The MUC1-C cytoplasmic domain contains a CQC motif that is necessary for MUC1-C homodimerization, localization to the nucleus and oncogenic function. The MUC1-C CQC motif is the target of the GO-203 inhibitor. C, CD34+ cells isolated from three patients with AML were treated with 2. These results were confirmed using THP1/MUC1shRNA cells ( Figure 5E , Figure S2D ). Inoculation of mice with MUC1shRNA/Vector cells did not lead to leukaemia induction. However, in experiments with the MUC1shRNA/surviving cells, 3/6 mice showed AML engraftment with mean levels of 2% blast involvement ( Figure 5F , G).
These findings indicate that MUC1 silencing leads to decreases in leukaemogenicity, at least in part by survivin downregulation.
| MUC1-C inhibition leads to increased susceptibility to cytarabine via down-regulation of survivin
We further sought to determine whether targeting MUC1-C with the resultant decrease in survivin levels would confer increased susceptibility to Ara-C. In this way, MOLM-14 cells were treated with increasing doses of Ara-C alone, GO-203 alone or the combination of both agents. Assessment of cell viability after 48 hours demonstrated dose-dependent cytotoxicity for each agent alone ( Figure 6A, B) . Figure 6G ).
| Low MUC1 and survivin expression in human AML is associated with increased overall survival
We hypothesized that increased MUC1 expression on human AML contributes to pathogenesis and predicted that AML with lower expression of MUC1 would be associated with better clinical outcomes. Consistent with this hypothesis, analysis of previously described group of 260 adult AML patients with diverse cytogenetic and molecular abnormalities 36 revealed that a dichotomous stratification of patients into low MUC1 and high MUC1 expression groups was associated with a significantly decreased risk of death in the low expressing group (P = .04) as demonstrated in Figure 7A . Similarly, association of survivin (BIRC5) expression and clinical outcomes was assessed. The data demonstrated that low survivin expression was correlated with statistically significant prolonged overall survival in this group of AML patients (P = .01; Figure 7B) . Interestingly, low expression of both MUC1 and survivin led to better clinical outcomes with higher statistical significance (P = .001; Figure 1C ). | 3895
These finding are consistent with previously published survival analysis using TCGA database demonstrating prolonged survival in AML patients with lower survivin expression. 37 Furthermore, our analysis of this database of 168 adult AML patients confirmed that patients with low MUC1 expression showed significantly prolonged overall survival (P = .02, data not shown).
| DISCUSSION
AML is a lethal haematological malignancy characterized by maturation arrest; the capacity for self-renewal and autonomous cell proliferation, resistance to apoptosis and increased resistance to cytotoxic injury. 
